Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients

Unresectable hepatocellular carcinoma (UHCC) is considered a chemoresistant disease, Moreover, because the liver underlies the disease, it decreases the tolerance to anticancer agents. Topotecan has shown some clinical activity in UHCC using the 5 days every 3 weeks schedule but is limited by severe hematotoxicity. Oxaliplatin is a diamino-cyclo-hexane-platin that exhibits in vitro synergy with topotecan. Thirteen UHCC patients received topotecan (0.5-1.5 mg/m(2)/d days 1-5) and oxaliplatin (85-110 mg/m(2)/d, day 1) every 21 days. All patients had liver biology within normal limits; I I had World Health Organization performance status less than 2. Seven patients had received previous chemotherapy. Nine patients without cirrhosis received a median number of six cycles (range: 3-12). The main dose-limiting toxicity was severe thrombocytopenia observed in three patients and 4% of cycles. One objective response and eight stabilizations were observed. Conversely, among 4 patients with cirrhosis receiving a median number of 2.5 cycles (range: 1-6), severe thrombocytopenia occurred in 2 patients and 25% of cycles. Three patients with progressive disease and one with stabilization were observed. Overall. the median duration of stabilizations was 27 weeks (range: 16-97 weeks). Four of seven patients treated with I mg/m(2)/d or more topotecan experienced severe toxicity. These results warrant a phase 11 study of this combination in noncirrhotic patients with UHCC. The recommended doses for further studies should be 0.5 mg/m(2)/d to 0.75 mg/m(2)/d of topotecan with 85 mg/m(2) Of oxaliplatin.